(Q28488506)

1

0 references

Tamar C Weenen

2

0 references

Harry Commandeur

3

0 references

Eric H J H M Claassen

Creative Commons Attribution 4.0 International

4

0 references

language of work or name

English

0 references

publication date

2013

0 references

published in

PLOS One

0 references

volume

8

0 references

issue

3

0 references

page(s)

e57755

0 references

copyright license

start time

20 March 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

The price of innovation: new estimates of drug development costs

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

Can the pharmaceutical industry reduce attrition rates?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

Development of new generation influenza vaccines: recipes for success?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

The gold industry standard for risk and cost of drug and vaccine development revisited

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

A comparison of the use of economics in vaccine expert reviews

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

Trends in risks associated with new drug development: success rates for investigational drugs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

The expanding vaccine development pipeline, 1995-2008.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

Human vaccine research and development: an overview

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

Anthrax, tularemia, plague, ebola or smallpox as agents of bioterrorism: recognition in the emergency room

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

The future of vaccines, immunisation concepts and practice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

Trends in infectious disease mortality in the United States during the 20th century

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

Vaccine manufacturing: challenges and solutions

29 September 2017

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0057755

Trial watch: Phase II failures: 2008-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0057755

Phase III and submission failures: 2007–2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0057755

Estimated research and development costs of rotavirus vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0057755

How the research-based industry approaches vaccine development and establishes priorities.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3603987

The 'not invented here' myth

27 November 2018

1 reference

12 December 2020

Vaccine R&D success rates and development times

1 reference

12 December 2020

The transition from phase II to phase III studies

1 reference

12 December 2020

Failure-to-success ratios, transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline

1 reference

12 December 2020

Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances

1 reference

12 December 2020

Getting pharmaceutical R&D back on target

1 reference

12 December 2020

How can we avoid the productivity gap?

1 reference

12 December 2020